leisure time -WSS

leisure time

author：Wikipedia 2025-09-30 20:47:25 - browse：1512

This image provided by Amylyx Pharmaceuticals shows the drug Relyvrio. The maker of a much-debated drug for Lou Gehrig’s disease said Friday, March 8, 2024 its therapy failed to help patients in a large follow-up study, but stopped short of committing to follow through on a prior pledge to pull the drug from the U.S. market. — Relyvrio, an ALS drug made by Amylyx Pharmaceuticals, failed to beat placebo in a key clinical trial. Amylyx Pharmaceuticals via AP

The latest disappointment in amyotrophic lateral sclerosis research brought crushing news for patients and physicians, forcing the community to consider just what to do with an approved medicine that doesn’t appear to work.

Amylyx Pharmaceuticals’ announcement Friday that its drug, marketed as Relyvrio, failed to beat placebo in a pivotal study marks “a sad day for us, but we have to believe the data,” said Mary Catherine Collet, an ALS advocate. “These are hard scientific facts that we have to face, and I appreciate that they’re not trying to spin us like some cheerleading practice.”

The question now is whether Relyvrio, approved in 2022, should be removed from the market entirely — and whether the Food and Drug Administration made a mistake by authorizing it in the first place. After years of pressure from patient advocates, the agency has taken a more flexible approach to medicines for devastating, incurable diseases like ALS. But the case of Relyvrio, which made $381 million in sales and $49 million in profit for Amylyx last year, has underlined questions about the limits of regulatory leniency.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： I learned firsthand about improving diversity in clinical trials

focus

WSS

Disclosing genetic information: not as worrisome as once feared

The battle over the Brookhaven Landfill on Long Island

Divers poised to search for children washed away in Pennsylvania flash flood

The story of mRNA: From a loose idea to a tool that may help curb Covid

The battle over the Brookhaven Landfill on Long Island

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

leisure time

leisure time

Drug repurposing or repositioning? The language matters

Colonoscopy at 40? Study finds a possible benefit

The cancer drug shortage isn’t new — and neither are the solutions

Ask STAT: What do you want to know about ChatGPT in medicine?

Walensky prepares to leave CDC — and Congress — behind

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

Trump demands the U.S. pay no more for drugs than other countries … again

The strategy behind pharma's lawsuits over drug pricing reform

United colonoscopy coverage change 'may cost lives,' doctors say

Death of patient in Alzheimer’s trial raises question of possible risks

hotspot

#NeedHerScience: shining a light on gender disparities in medicine

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

#NeedHerScience: shining a light on gender disparities in medicine

CDC concerned about possible undetected monkeypox spread in U.K.

CDC concerned about possible undetected monkeypox spread in U.K.

Vir antibody drug aimed at influenza A fails in clinical trial

knowledge

explore

focus

explore